angelo

Japan is seeking to boost its presennce in South Africa by offering an energy transition loan and a technology that allows ammonia to be blended with coal to reduce power plant emissions bloomberg.com/news/articles/…

ICYMI | @JapanChair welcomed members from Japan's House of Representatives and an expert from the University of Tokyo to discuss security dynamics in Asia and​ ​the outlook for U.S.-Japan relations. Watch: csis.org/events/whats-n…

@azplanetaz お上手です

やっぱり絵が好きだ

While the world has been focused on the US-Israeli war on Iran and its fallout, the Israeli government has accelerated the de facto annexation of the West Bank. chathamhouse.org/2026/04/israel…

The herpes simplex virus type 1 (HSV-1), the same virus responsible for cold sores in billions of people worldwide, is being genetically engineered into a potent new cancer therapy. Scientists are reprogramming this virus into oncolytic viruses designed to selectively infect, replicate within, and destroy tumor cells while sparing healthy tissue. Once injected into a tumor, the modified virus multiplies rapidly until the cancer cell bursts. Beyond this direct cell-killing effect, the destruction of tumor cells releases tumor-specific antigens and danger signals that activate the patient’s immune system. This triggers a broader systemic immune response capable of attacking cancer cells not only at the injection site but also at distant, untreated tumors. Early clinical results have been encouraging. In advanced melanoma patients who had already failed standard immunotherapies, combination treatment with the oncolytic HSV-1 RP1 (vusolimogene oderparepvec) and nivolumab produced meaningful responses in approximately one-third of participants, with some experiencing complete tumor disappearance. Side effects are generally mild to moderate, often limited to flu-like symptoms such as fever and fatigue. Larger phase 3 trials are now underway to confirm these benefits across broader patient populations. While still in development, this approach represents a promising new frontier in cancer immunotherapy, transforming a lifelong virus into a precision tool that helps the immune system recognize and eliminate tumors. [Andtbacka, R. H. I. et al. Efficacy and safety of vusolimogene oderparepvec plus nivolumab in patients with advanced melanoma that progressed on anti–PD-1 therapy: Results from the IGNYTE trial. Journal of Clinical Oncology (2025). DOI: 10.1200/JCO-25-01346]

あらあら。ハンガリーおかえりのすぐ後にこれすか。

"While Iran is losing on the battlefield, it is competing effectively in the information space through an aggressive, multiplatform disinformation campaign," writes @csisfutures. Read their new report that analyzed 9,000+ social media posts: csis.org/analysis/tappi…

死ぬまで本当の才能に気づけないよりかはましかもね

なにー

ついにー

@part329310623 私はバケモノかもしれないバージョンも見たいなぁー🤫

てもて～🤲

こう言うことやったんか。

どこもかしこも倫理倫理でがんじがらめのようです！！🫡

今日、娘の保育園で今日はスターウォーズの日だぜ！って先生に言われて学校で決めた今日のテーマかなと思ったら。本当にそうだったのね。

@1mdIst 面白そう。ブックマークさせていただきます！

この本めちゃくちゃよい！ 労働は苦役なのか？労働の合間にしか余暇や遊びがないのは何故なのか？って本 ボヤけた頭で寝ながら読むんじゃなかった。 また明日読む

さぁ、紙の上ではもう停戦してるぜよと。。

センスよ！！😳

憲法の職業選択の自由のが強い拘束力があると考えましたので、迷わず押させていただきます🙇🏻‍♂️

we are gonna do something nice for everyone who applied for the GPT-5.5 party and that we didn't have space for. hope you enjoy!

60日間しか権限がない大統領権限での軍事行動が紙の上でどのように処理されるか。そして現実との乖離がどの程度になるのか。気になる。。